FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215966090> ?p ?o ?g. }

• W3215966090 endingPage "1959" @default.
• W3215966090 startingPage "1959" @default.
• W3215966090 abstract "Bladder cancer is the 10th most diagnosed cancer, with almost 10 M cancer deaths last year worldwide. Currently, chemotherapy is widely used as adjuvant therapy after surgical transurethral resection. Paclitaxel (PTX) is one of the most promising drugs, but cancer cells acquire resistance, causing failure of this treatment and increasing the recurrence of the disease. This poor chemotherapeutic response has been associated with the overexpression of the protein survivin. In this work, we present a novel dual nano-treatment for bladder cancer based on the hypothesis that the inhibition of survivin in cancer cells, using a siRNA gene therapy strategy, could decrease their resistance to PTX. For this purpose, two different polymeric nanoparticles were developed to encapsulate PTX and survivin siRNA independently. PTX nanoparticles showed sizes around 150 nm, with a paclitaxel loading of around 1.5%, that produced sustained tumor cell death. In parallel, siRNA nanoparticles, with similar sizes and loading efficiency of around 100%, achieved the oligonucleotide transfection and knocking down of survivin expression that also resulted in tumor cell death. However, dual treatment did not show the synergistic effect expected. The root cause of this issue was found to be the cell cycle arrest produced by nuclear survivin silencing, which is incompatible with PTX action. Therefore, we concluded that although the vastly reported role of survivin in bladder cancer, its silencing does not sensitize cells to currently applied chemotherapies." @default.
• W3215966090 created "2021-12-06" @default.
• W3215966090 creator A5004660816 @default.
• W3215966090 creator A5026090003 @default.
• W3215966090 creator A5047553777 @default.
• W3215966090 creator A5076148230 @default.
• W3215966090 date "2021-11-19" @default.
• W3215966090 modified "2023-10-16" @default.
• W3215966090 title "Role of Survivin in Bladder Cancer: Issues to Be Overcome When Designing an Efficient Dual Nano-Therapy" @default.
• W3215966090 cites W1490361387 @default.
• W3215966090 cites W1979618048 @default.
• W3215966090 cites W1992358749 @default.
• W3215966090 cites W2016132577 @default.
• W3215966090 cites W2027730833 @default.
• W3215966090 cites W2028325904 @default.
• W3215966090 cites W2030429038 @default.
• W3215966090 cites W2037798739 @default.
• W3215966090 cites W2041056208 @default.
• W3215966090 cites W2073182207 @default.
• W3215966090 cites W2080924552 @default.
• W3215966090 cites W2088564088 @default.
• W3215966090 cites W2095412415 @default.
• W3215966090 cites W2096096240 @default.
• W3215966090 cites W2101922970 @default.
• W3215966090 cites W2111424797 @default.
• W3215966090 cites W2121631991 @default.
• W3215966090 cites W2136404433 @default.
• W3215966090 cites W2137434148 @default.
• W3215966090 cites W2149787400 @default.
• W3215966090 cites W2151390274 @default.
• W3215966090 cites W2158276831 @default.
• W3215966090 cites W2317538561 @default.
• W3215966090 cites W2319797080 @default.
• W3215966090 cites W2320079826 @default.
• W3215966090 cites W2335125141 @default.
• W3215966090 cites W2344644350 @default.
• W3215966090 cites W2567092281 @default.
• W3215966090 cites W2586783706 @default.
• W3215966090 cites W2783757852 @default.
• W3215966090 cites W2790635169 @default.
• W3215966090 cites W2790653451 @default.
• W3215966090 cites W2794641241 @default.
• W3215966090 cites W2801790983 @default.
• W3215966090 cites W2804334909 @default.
• W3215966090 cites W2809044246 @default.
• W3215966090 cites W2896000804 @default.
• W3215966090 cites W2902850817 @default.
• W3215966090 cites W2936221437 @default.
• W3215966090 cites W2943769781 @default.
• W3215966090 cites W2963065854 @default.
• W3215966090 cites W2971651032 @default.
• W3215966090 cites W2980852499 @default.
• W3215966090 cites W3011893581 @default.
• W3215966090 cites W3044226803 @default.
• W3215966090 cites W3048531353 @default.
• W3215966090 cites W3128646645 @default.
• W3215966090 cites W3151520177 @default.
• W3215966090 cites W3161044173 @default.
• W3215966090 cites W4211199440 @default.
• W3215966090 doi "https://doi.org/10.3390/pharmaceutics13111959" @default.
• W3215966090 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8618611" @default.
• W3215966090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34834374" @default.
• W3215966090 hasPublicationYear "2021" @default.
• W3215966090 type Work @default.
• W3215966090 sameAs 3215966090 @default.
• W3215966090 citedByCount "5" @default.
• W3215966090 countsByYear W32159660902022 @default.
• W3215966090 countsByYear W32159660902023 @default.
• W3215966090 crossrefType "journal-article" @default.
• W3215966090 hasAuthorship W3215966090A5004660816 @default.
• W3215966090 hasAuthorship W3215966090A5026090003 @default.
• W3215966090 hasAuthorship W3215966090A5047553777 @default.
• W3215966090 hasAuthorship W3215966090A5076148230 @default.
• W3215966090 hasBestOaLocation W32159660901 @default.
• W3215966090 hasConcept C104317684 @default.
• W3215966090 hasConcept C119056186 @default.
• W3215966090 hasConcept C121608353 @default.
• W3215966090 hasConcept C126322002 @default.
• W3215966090 hasConcept C185592680 @default.
• W3215966090 hasConcept C190283241 @default.
• W3215966090 hasConcept C2775975398 @default.
• W3215966090 hasConcept C2776694085 @default.
• W3215966090 hasConcept C2777292972 @default.
• W3215966090 hasConcept C2780352672 @default.
• W3215966090 hasConcept C502942594 @default.
• W3215966090 hasConcept C55493867 @default.
• W3215966090 hasConcept C71924100 @default.
• W3215966090 hasConcept C96232424 @default.
• W3215966090 hasConceptScore W3215966090C104317684 @default.
• W3215966090 hasConceptScore W3215966090C119056186 @default.
• W3215966090 hasConceptScore W3215966090C121608353 @default.
• W3215966090 hasConceptScore W3215966090C126322002 @default.
• W3215966090 hasConceptScore W3215966090C185592680 @default.
• W3215966090 hasConceptScore W3215966090C190283241 @default.
• W3215966090 hasConceptScore W3215966090C2775975398 @default.
• W3215966090 hasConceptScore W3215966090C2776694085 @default.
• W3215966090 hasConceptScore W3215966090C2777292972 @default.
• W3215966090 hasConceptScore W3215966090C2780352672 @default.

• next